Rectal cancer treatment: Improving the picture

Table 1 Novel chemoradiation combinations

	Chemotherapy		RT (Gy)	GI grade 3-4 toxicity (%)	DS (%)	pCR (%)
	Capecitabine (mg/m2 bid)
Kim et al	825 d 1-14 and 22 - 35		50.4	-	84	31
De Paoli et al	825 bid continuous		50.4	-	57	24
	5-FU (mg/m2 CI)	CPT-11 (mg/m2 weekly)
Mehta et al	200	50	50.4	28	71	37
Klautke et al	250	40	50.4	32	76	24
Mohiuddin et al	Arm 1: 225	Arm 1: -	HART: 55.2-60	27	78	26
	Arm 2: 225	Arm 2: 50	50-54	37	78	26
Navarro et al	225	50	45	14	49	14
	5-FU (mg/m2 CI)	Oxaliplatin (mg/m2)
Ryan et al	200	MTD: 60 weekly	50.4	38	-	25
Aschele et al	200-225	MTD: 60 weekly	50.4	16	84	28
Turrito et al	300	80 wk 1, 3, 5	45	-	65	15
	Capecitabinec (mg/m2 bid)	Oxaliplatin (mg/m2)
Rodel et al	825 d 1-14 and 22 - 35	50 d 1, 8, 22	50.4	6	55	19
Machiels et al	825 bid continuous	50 weekly	45	30	-	14

RT: Radiotherapy; DS: Downstaging; bid:Twice daily; CI: Continuous infusion; HART: Hyperfractionated accelerated radiotherapy; MTD: Maximun-tolerated-dose; GI: Gastrointestinal.